Surrozen reports FY2025 net loss $242M; cash $89.2M; expects IND for SZN-8141 in H2 2026

Surrozen, Inc./DE

Cash and equivalents $89.2M at Dec 31, 2025, up from $34.6M year-end 2024; additional $30.2M raised in early 2026 via ATM and warrant exercises.
Full year net loss $242.0M ($32.37 per share) vs $63.6M in 2024, driven by non-cash PIPE-related charges (tranche liability, warrant revaluation).
No collaboration revenue in 2025 vs $10M in 2024; research service revenue from terminated TCGFB deal was $3.5M.
Received $5M milestone from Boehringer Ingelheim for SZN-413 after successful IND-enabling GLP tox study.
On track to submit IND for SZN-8141 (retinal disease) to FDA in H2 2026; will present at ARVO in May 2026.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Surrozen, Inc./DE reported fourth quarter and full year 2025 results: revenue $0.5 million and $3.5 million for the quarter and year ended December 31, 2025.

Period: fourth quarter and full year 2025
Revenue: $0.5 million and $3.5 million for the quarter and year ended December 31, 2025
Result: reported results

Exact text from the filing

On March 23, 2026, Surrozen, Inc. (the “Company”) issued a press release announcing its financial results for the year ended December 31, 2025.

View on SEC.gov

Browse all earnings releases →

Surrozen, Inc./DE filing history →

Source: SEC EDGAR

accession 0001193125-26-119757

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.